Where can I find news about LABU?

Press releases, SEC filings, and prospectus updates from the fund issuer are listed on this page. Direxion Daily S&P Biotech Bull 3X Shares (LABU) news is sourced from regulatory filings and the issuer's investor relations feed.

How can I track LABU's SEC filings?

LABU's 485APOS / 485BPOS prospectus filings, N-CSR shareholder reports, and other regulatory filings are listed on this page with direct links to the SEC EDGAR copies. Filings update as the issuer submits them — typically semi-annually for shareholder reports.

Where can I find LABU's prospectus?

Direxion Daily S&P Biotech Bull 3X Shares (LABU)'s most recent prospectus is linked in the filings section on this page. Issuers publish the full prospectus on their product page and re-file it annually with material updates flagged in the 485BPOS amendment.

LABU

Direxion Daily S&P Biotech Bull 3X Shares

AMEX·Asset Management · Financial Services

$253.77$0.09+0.04%

After hours·$252.46−0.52%

Market closed·Jul 23 8:00 PM UTC

Press Releases

LABU Could Rip Higher if Biotech Finally Gets Its Long-Awaited Breakout
If you bought XBI a year ago and held it, you are up roughly 65%. If you bought Direxion Daily S&P Biotech Bull 3X Shares (NYSEARCA:LABU) on the same day, you are up about 235%.
247wallst.comApr 27, 2026 · 3:33 PM
Equal-Weight ETFs Are the Play for Small-Cap Drug Development. Here's How to Position Now
Biotech has reasserted itself over the past year as drug approvals,
247wallst.comApr 23, 2026 · 1:22 PM
34,270 Shares in Direxion Daily S&P Biotech Bull 3x Shares $LABU Purchased by JPMorgan Chase & Co.
JPMorgan Chase and Co. purchased a new stake in Direxion Daily S&P Biotech Bull 3x Shares (NYSEARCA:LABU) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 34,270 shares of the company's stock, valued at approximately $3,208,000. JPMorgan Chase and
defenseworld.netApr 5, 2026 · 4:47 AM
Direxion Daily S&P Biotech Bull 3x Shares (NYSEARCA:LABU) Shares Gap Down – Here’s Why
Direxion Daily S&P Biotech Bull 3x Shares (NYSEARCA:LABU - Get Free Report) gapped down prior to trading on Friday. The stock had previously closed at $170.74, but opened at $164.08. Direxion Daily S&P Biotech Bull 3x Shares shares last traded at $165.2680, with a volume of 83,975 shares traded. Direxion Daily S&P Biotech Bull
defenseworld.netFeb 22, 2026 · 3:26 AM
Triple-Leveraged Biotech ETF Doubles as Regulatory Winds Shift in 2026
Triple-leveraged ETFs aren't for everyone, but if you believe biotech is about to break out, Direxion Daily S&P Biotech Bull 3X Shares (NASDAQ:LABU) offers the most aggressive way to capture that move.
247wallst.comJan 16, 2026 · 8:06 AM
Direxion Daily S&P Biotech Bull 3x Shares (NYSEARCA:LABU) Hits New 1-Year High – What’s Next?
Direxion Daily S&P Biotech Bull 3x Shares (NYSEARCA:LABU - Get Free Report)'s stock price hit a new 52-week high during mid-day trading on Thursday. The company traded as high as $186.25 and last traded at $175.81, with a volume of 1797531 shares changing hands. The stock had previously closed at $159.31. Direxion Daily S&P
defenseworld.netJan 10, 2026 · 4:56 AM
Navigate Biotech's Crosscurrents With Direxion's LABU And LABD ETFs
Although the equities market often embodies chaos and capricious non-linearity, few sectors witness as much kinetic wildness like biotechnology. At its core, biotech represents an innovative push toward addressing the human condition — which is often found to be shockingly frail.
benzinga.comDec 18, 2025 · 8:30 AM
Direxion Daily S&P Biotech Bull 3x Shares (NYSEARCA:LABU) Reaches New 52-Week High – What’s Next?
Direxion Daily S&P Biotech Bull 3x Shares (NYSEARCA:LABU - Get Free Report) shares hit a new 52-week high during mid-day trading on Friday. The company traded as high as $169.50 and last traded at $167.9060, with a volume of 88167 shares changing hands. The stock had previously closed at $166.04. Direxion Daily S&P Biotech
defenseworld.netDec 7, 2025 · 2:40 AM

Fund Documents

Summary Prospectus497K
Jul 15, 2026View
Prospectus485BPOS
Jul 21, 2026View
Semi-Annual ReportN-CSRS
Jul 8, 2026View
Portfolio HoldingsNPORT-P
Jun 29, 2026View

View all filings on SEC EDGAR

Frequently Asked Questions About LABU

Where can I find news about LABU?: Press releases, SEC filings, and prospectus updates from the fund issuer are listed on this page. Direxion Daily S&P Biotech Bull 3X Shares (LABU) news is sourced from regulatory filings and the issuer's investor relations feed.
How can I track LABU's SEC filings?: LABU's 485APOS / 485BPOS prospectus filings, N-CSR shareholder reports, and other regulatory filings are listed on this page with direct links to the SEC EDGAR copies. Filings update as the issuer submits them — typically semi-annually for shareholder reports.
Where can I find LABU's prospectus?: Direxion Daily S&P Biotech Bull 3X Shares (LABU)'s most recent prospectus is linked in the filings section on this page. Issuers publish the full prospectus on their product page and re-file it annually with material updates flagged in the 485BPOS amendment.

Direxion Daily S&P Biotech Bull 3X Shares

Frequently Asked Questions About LABU

Direxion Daily S&P Biotech Bull 3X Shares

LABU Could Rip Higher if Biotech Finally Gets Its Long-Awaited Breakout

Equal-Weight ETFs Are the Play for Small-Cap Drug Development. Here's How to Position Now

34,270 Shares in Direxion Daily S&P Biotech Bull 3x Shares $LABU Purchased by JPMorgan Chase & Co.